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ABSTRACT
An imbalance between calorie intake and energy expenditure produces obesity. It has been a major problem
in societies of the developing and developed world. In obesity an excessive amount of fat accumulates in
adipose tissue cells as well as in other vital organs like liver, muscles, and pancreas. The adipocytes contain
ob genes and express leptin, a 16 kDa protein. In the present communication, we reviewed the molecular
basis of the etiopathophysiology of leptin in obesity. Special emphasis has been given to the use of leptin as
a drug target for obesity treatment, the role of diet in the modulation of leptin secretion, and reduction of
obesity at diminished level of blood leptin induced by physical exercise.
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INTRODUCTION
Obesity is a major health issue in much of the human population [1]. Increasingly it has become
a serious medical problem in developing nations due to urbanization and a more plentiful food
supply [2]. Food intake is a complex behavior, which is determined by conscious decision-
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making and subject to environmental factors such as the availability and properties of foods as
well as social and cultural norms.
Appetite is a subjective feeling of the motivation to eat. Hunger and satiety can be overridden
by desire. Our food preferences and eating patterns are molded by past experiences and also get
influenced by sight, smell, and taste sensations. Eating behavior thus involves a complex
interaction between different physiological processes [3].
Physiologically obesity is a disorder of energy balance, where energy in excess of its
expenditure is stored as fat. The suppression of food intake and the increase in energy expen-
diture will therefore be very much effective for the treatment of obesity. It is also a part of the
metabolic syndrome that increases the risk of abdominal fat deposition, insulin resistance,
dyslipidemia, hypertension, coronary artery disease, fatty liver, gall stones, arthritis, cancer and
may shorten the life span [4].
Several genes have been identified which can maintain body weight within a normal
range. A key element of this system is ‘leptin’, the 16-kDa hormonal product of the obese (ob)
gene, which was first identified in the year 1994 [5]. In humans, leptin is primarily secreted by
white adipose tissues, which in fact corroborates its hormone function. Food intake and body
weight are decreased by the action of leptin through its hypothalamic receptors [6]. Leptin
increases insulin sensitivity and regulates glucose metabolism [7]. It acts as a growth factor in
different cells [8] and in humans it regulates metabolic, neuroendocrine and immunological
functions, which in turn maintain energy homeostasis [9]. In newborn infants, children, and
adults, the amount of circulating leptin is generally proportional to fat mass, in which the
amount of stored energy represents the balance between ingested calories and energy
expenditure [5].
Leptin conveys information to the central nervous system (CNS) about the available energy
stores in the body. The absence of leptin or its receptors therefore induces appetite and food
intake that result in morbid obesity. Obese adults usually have elevated leptin levels, and leptin
cannot induce weight loss due to cellular resistance to leptin [10]. However, leptin deficiency is
found to occur in the exceptional cases of severe early childhood obesity. In the present
communication we summarize the current understanding of the role of leptin in development
and management of obesity at the cellular level.
BIOLOGY OF LEPTIN
ob Gene
The hormone leptin comes from the Greek word “leptos” meaning “thin”. In humans leptin is
encoded by the ob gene, which is located on chromosome 7 and comprises three exons and two
introns spanning 20 kilobases (kb) of genomic DNA [11]. Transcription of the leptin gene in
mice yields a mRNA of about 3.5 kb that is expressed primarily in adipose tissues and also in
placenta, ovaries, skeletal muscle, and stomach [12–15]. Leptin is synthesized as a 167 amino
acid protein with a secretory signal sequence of 21 amino acid residues at the amino terminus.
The signal sequence is functional, and results in the translocation of leptin into microsomes with
subsequent removal of the signal peptide. Therefore the circulating leptin contains 146 amino
acid residues [5]. A positive correlation exists between leptin mRNA and leptin protein levels in
adipose tissue and plasma. Leptin is similar to cytokines. The structure of leptin consists of a
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complex of four helices and an intrachain disulphide bond, which is necessary for its biological
activity [16, 17]. Mutations of the ob gene cause early onset of obesity in mice. Thus ob/ob
mouse mutants become leptin-deficient, hyperphagic, hypothermic, and exhibit morbid obesity
with multiple metabolic and neuroendocrine anomalies. Human ob gene mutations also cause
similar changes along with hypothalamic hypogonadism [16].
Leptin circulation
Leptin circulates at a concentration of 5 mg/ml to 15 mg/ml in lean individuals. Women have
higher circulating levels of leptin than men. Such sex difference may be associated with a
stimulating role of estrogen or a suppressing role of androgens on leptin production [18]. Leptin
circulates in plasma either as free adipokines or in bound form coupled to its receptor-binding
proteins. In lean individuals the great majority of leptin circulates in the bound form, whereas in
obese individuals it circulates in the free form [19].
Regulation of Leptin Secretion
Leptin synthesis is stimulated by insulin, cortisol, endotoxin, and cytokines like leukemia
inhibitory factor (LIF) and interleukin-1 (IL-1). It is downregulated by catecholamines, thyroid
hormone, testosterone, cAMP, and thiazolidine derivatives. In addition to these factors, tumor
necrosis factor-a (TNF-a) serves as a paracrine regulator to increase the secretion of leptin.
Leptin can also autoregulate its own expression by glucose and fatty acids [16].
Leptin receptor (ob-R) gene
The leptin receptor (ob-R) gene was first isolated from mouse choroid plexus using an
expression cloning strategy. Several splice variants of ob-R mRNA encode a minimum number
of 6 isoforms of leptin receptors. Leptin receptor mutations cause early onset obesity accom-
panied by leptin insensitivity, hyperphagia, metabolic derangement, morbid obesity, and
neuroendocrine abnormalities, including hypercorticism and hypothalamic hypogonadism. In
humans this type of mutation brings about similar changes accompanied by impairment in the
secretion of thyrotropin and growth hormone [16].
Leptin receptors
Leptin receptors belong to the cytokine class I receptor family. Several alternatively spliced
isoforms of the leptin receptor have been identified (ob-Ra, ob-Rb, ob-Rc, ob-Rd, and ob-Re)
[20]. Leptin receptor isoforms share an identical extracellular ligand binding domain at the
amino terminus but differ at the carboxy terminus. Five isoforms, ob-Ra, ob-Rb, ob-Rc, ob-Rd,
and ob-Re have transmembrane domains; however, only ob-Rb contains intracellular motifs
required for its activity [16].
The ob-Ra is a leptin transporter and ob-Re is the soluble form of the transmembrane leptin
receptor [21]. The long isoform of the leptin ob-Rb receptor consists of 1162 amino acids, with
an intracellular signaling domain. It shows high peak concentrations in the feeding centers of the
hypothalamus. The circulating leptin crosses the blood–brain barrier (BBB) to bind to its hy-
pothalamic receptors and activates the JAK-STAT3 pathway. This suggests that leptin is the
afferent signal informing the central nervous system about the body fat status. The neuronal-
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specific ablation of ob-Rb leads to obesity. On the other hand, high concentrations of the short
isoforms of the ob-Ra and ob-Rc receptors are found in choroid plexus and brain microvessels,
suggesting their role in BBB transport. The secreted isoform can be generated either by alter-
native splicing (ob-Re) or by ectodomain shedding, which may be involved in modulating leptin
activity [20]. Moreover, leptin receptors are also found in different peripheral tissues viz. liver,
heart, kidneys, lungs, small intestine, pituitary cells, testes, ovaries, spleen, pancreas and adrenal
glands [22].
Leptin signaling
The structure of leptin is related to that of the long-chain helical cytokine family. The main
channel of this gene is JAK/STAT. It acts via two groups of arcuate neurons, which are located in
the hypothalamus region of the brain. The first group expresses agouti-related peptide (AgRP)
and neuropeptide Y (NPY) and the second group expresses pro-opiomelanocortin (POMC) and
cocaine and amphetamine-related transcript (CART) [23].
Binding of leptin to its long form of the surface membrane receptor (ob-Rb) of the target
cells causes dimerization of its receptors, which in turn activates the JAK/STAT pathway [24].
The activated JAKs phosphorylate tyrosine sites on the intracellular domain of the receptor,
which serve as docking sites for the Src-homology domains (SH2, SH3) that occur in all of the
STATs. The phosphorylated intracellular domain has a binding site for STAT protein. The
activated STAT proteins undergo dimerization and then translocate to the nucleus. The acti-
vation, dimerization, and nuclear translocation of STAT3 enhances POMC gene expression and
inhibits AgRP gene expression. Accordingly, POMC neurons deficient in STAT3 result in
enhanced bodyweight. This signaling pathway is negatively controlled by the suppression of
cytokine signaling 3 (SOCS3), the expression of which is in turn under the regulation of the
activities of STAT3 and protein tyrosine phosphatase 1B (PTP1B). Consistent with this, deletion
of either SOCS3 or PTP1B (Ptpn1) in POMC neurons leads to reduced adiposity, improved
leptin sensitivity, and increased energy expenditure [25]. ob-Rb activation may also phos-
phorylate JAK leading to the activation of insulin receptor substrate (IRS-1) and mitogen-
activated protein kinase (MAPK) [2].
Upon binding of leptin to its ob-Ra receptor, IRS-1 gets phosphorylated and activates
MAPK, resulting in the activation of pp90S6-K [25]. In addition, leptin also stimulates the
phosphatidylinositol-3-kinase (PI3K) pathway. PI3K generates phosphatidylinositol-3,4,5-
triphosphate (PIP3) and activates downstream targets such as phosphoinositide-dependent
kinase 1 (PDK1) and AKT (also known as protein kinase B), which consecutively phos-
phorylate the transcription factor forkhead box protein O1 (FOXO1). Upon phosphorylation,
FOXO1 is excluded from the nucleus, allowing STAT3 to bind to POMC and AgRP pro-
moters, thereby stimulating and inhibiting, respectively, the expression of these neuropeptides
[26]. PI3K signaling is counterbalanced by phosphatase and tensin homolog (PTEN), which
specifically dephosphorylate PIP3. The loss of PTEN in POMC neurons brings about increased
PIP3 signaling and diet-sensitive obesity via KATP channel modulation, suggesting a role for
the PI3K pathway in the regulation of the activity of this channel [25]. Thus, leptin stimulates
POMC transcription and depolarizes POMC neurons. It also increases a-MSH processing and
secretion and attenuates the expression and release of orexigenic NPY and AgRP neuropep-
tides [3].
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IMPLICATIONS OF LEPTIN IN OBESITY
Leptin is the chemical mediator in the brain responsible for the conditions of energy imbalance,
such as obesity. The most important variable that determines circulating leptin concentrations is
body fat mass [27]. When eating cycles are regular, an exponential relationship exits between the
level of leptin and the proportion of adipose tissue. Human obesity is related with hyperleptinemia
and the circulating leptin concentrations are predicted by the body mass index (BMI). The ob gene
is expressed in different fat compartments of the body. Approximately 5% of obese populations
can be regarded as “relatively” leptin deficient, which would benefit from leptin therapy [20].
Leptin has dual regulation in human physiology. During the time of weight maintenance, the
intake of energy is equal to the energy output, and leptin concentrations reflect total body fat
mass. However, in the cases of negative (weight-loss programs) and positive (weight-gain
programs) energy balances, the changes in leptin concentrations act as a sensor of energy
imbalance [20]. In absolute leptin deficiency, individuals with heterozygous leptin gene muta-
tions have low circulating concentrations of leptin resulting in an increase in body adiposity
[20]. Independent of fat mass, low soluble leptin receptor concentrations and a low ratio of
bound to free leptin have been found in individuals with insulin resistance and abdominal
obesity. On the other hand, low soluble receptor concentrations and a low fraction of specifically
bound leptin are the markers of leptin resistance, which are independently associated with
insulin resistance and abdominal obesity [28]. Leptin can regulate adipocyte mass and modulate
immune responses including chronic inflammation in peripheral tissues. Thus, obesity is
strongly associated with inflammatory state as evidenced by high levels of cytokines and in-
flammatory markers within the body [29].
EFFECTS OF LEPTIN IN FASTING CONDITION
The dominance of leptin in energy homeostasis acts as a mediator of adaptation to fasting. When
both lean and obese individuals undergo short-term fasting, there is a larger decrease in free
leptin concentrations in lean subjects than in obese individuals. In obese individuals leptin
concentration in the cerebrospinal fluid increases modestly and the ratio of leptin in the cere-
brospinal fluid to that in serum decreases logarithmically with increasing BMI [30]. Leptin-
deficient ob/ob mice exhibit similar metabolic, neuroendocrine, and immune abnormalities as
those resulting from starvation. These changes suggest that leptin deficiency is perceived as a state
of continuous starvation in ob/ob mice, and also that the fall in leptin level mediates the adap-
tation to fasting by regulating the hypothalamic–pituitary–adrenal axis [16], and evokes profound
changes in energy balance and hormone levels. This in turn limits the use of energy and enhances
energy storage in the form of fat. Thus, leptin provides protection against starvation [3].
EFFECTS OF LEPTIN ON FOOD INTAKE
Leptin plays a key role in the control of food intake. Several studies have demonstrated that in
rodents leptin is transported into the brain and binds to its receptor in the hypothalamus to
activate the JAK-STAT3 pathway. This in turn results in the suppression of “orexigenic
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peptides” (e.g., NPY, AgRP, and GABA which normally increase food intake), and stimulation
of “anorexigenic peptides” (e.g., POMC and CART which normally decrease food intake) [3].
The hyperphagic behavior is evident in ob/ob and db/db mice. Food intake gets significantly
suppressed in ob/ob mice when leptin is injected into them either centrally or peripherally.
Disruption of the LepR/STAT3 pathway produces hyperphagia. Multiple neuronal populations
and neurocircuits on which leptin can act regulate food intake and energy balance. The
disruption of LepR expression exclusively in POMC/CART or NPY/AgRP/GABA neurons ex-
erts profound effects on food intake and energy balance. In the lateral hypothalamic area (LHA)
there are some neurons which express the neuropeptides melanin-concentrating hormone
(MCH) or orexin (also known as hypocretin). These cells do not express the LepR and stimulate
feeding. On the other hand, the neurotensin-positive neurons of LHA express LepR, and the
ablation of LepR in these cells increases food intake. Leptin acts in LHA neurotensin neurons
resulting in the inhibition of orexin neurons. In addition, in mice the pharmacogenetic acti-
vation of LepR-expressing neurons in the median preoptic area (MPO) causes a massive sup-
pression of food intake. Dopamine neurons in the ventral tegmental area (VTA) express LepR
and thus the direct administration of leptin to the VTA leads to a decrease in food intake [31].
LepR-expressing cells in the nucleus tractus solitarious (NTS) also express different neuro-
chemical markers like POMC, cholecystokinin (CCK) and glucagon-like peptide-1 (GLP-1) [32].
Selective inactivation of LepR in Phox2b-positive cells causes LepR deletion in NTS GLP-1
neurons. This genetic manipulation generates mice that display increased food intake after
fasting, indicating that leptin action on GLP-1 neurons also controls food intake [33].
Leptin also plays a role in short-term regulation of food intake and body weight. In addition
to adipose tissue, leptin is also produced by the stomach in small amounts [15]. The conser-
vation of leptin across different species and diverse organs points to the functional relevance of
this adipokine [34]. Leptin plays a role in the control of meal size; several intestinal peptides as
well as insulin stimulate the release of leptin from the stomach. The pancreatic hormone insulin
is secreted into the bloodstream shortly after the intake of food. Furthermore, high-fat meals and
mixed meals decrease the circulating leptin levels in a day. Thus gastric leptin acts as a local
stimulus in the intestinal digestion and absorption of the ingested foods [35].
EFFECTS OF LEPTIN ON ENERGY EXPENDITURE AND THERMOGENESIS
In humans there are two classes of adipose tissues, namely white adipose tissue (WAT) and
brown adipose tissue (BAT). During fasting the chemical energy stored in the form of tri-
acylglycerols in the WAT is utilized. BAT contains triacylglycerols, large numbers of mito-
chondria and profuse sympathetic adrenergic innervation which are responsible for its brown
color. The uncoupling protein 1 (UCP1) expressed by BAT causes its mitochondria to release
the energy as heat by the oxidation of macronutrients [36, 37]. In obese humans there is a
reduction in or absence of the amount and activity of BAT [38].The process by which WAT is
converted to BAT by increasing the number of its mitochondria and the expression of UCP1 is
called “browning”. This process increases energy expenditure and inhibits high-fat diet-induced
obesity in rodents [39]. Nowadays BAT is a potential target for obesity treatment. [40].
Leptin has potential effects on energy expenditure. ob/ob mice show high metabolic effi-
ciency due to low energy expenditure, which can be corrected by leptin replacement in these
460 Physiology International 107 (2020) 4, 455–468
mice [31]. Actually, the regulation of energy expenditure by leptin depends on multiple neuronal
populations. The ablation of LepR in AgRP neurons or in POMC and AgRP cells causes obesity
in adult mice due to alteration in energy expenditure without affecting the food intake [41].
Leptin also acts on the dorsomedial nucleus of the hypothalamus (DMH) and increases sym-
pathetic tone to brown adipose tissue (BAT) as well as interscapular BAT temperature [42, 43].
The selective disruption of LepR in DMH neurons causes obesity due to low energy expenditure
and the inhibition of thermogenic responses to leptin, without affecting food intake [44, 45]. In
humans leptin acts on POMC neurons to promote the browning of WAT as well as energy
expenditure and also to depress appetite [40].
Leptin regulates energy balance through its actions in the hypothalamus. Despite high
circulating levels of leptin in obese people, the hypothalamus does not sensitize leptin to sup-
press appetite or to increase energy expenditure probably due to an abnormal transit across the
BBB at the arcuate nucleus, hypothalamic endoplasmic reticulum (ER) stress, maladaptive sterile
inflammation in the hypothalamus, and overexpression of molecules that may inhibit leptin
signaling. In addition, the NSAPP pathway (consisting of five protein components) is needed for
the complete signaling of leptin in neurons and in the case of obesity this pathway cannot
function properly. Thus in obesity leptin cannot exhibit its appetite-suppressing effects resulting
in leptin resistance [36].
LEPTIN RESISTANCE AND OBESITY
Obesity is characterized by a condition of leptin resistance. The failure of high endogenous
leptin to normalize body weight in obese individuals has suggested the possibility of develop-
ment of leptin resistance in obesity [46]. The obese human shows elevated levels of leptin in
serum and adipocytes, and exhibits limited effects with leptin treatment due to leptin-resistance.
In diet-induced obesity (DIO) overeating causes an increase in circulating leptin levels leading to
a reduced sensitivity of the hypothalamus to leptin [31]. In addition, rats develop leptin resis-
tance in chronic leptin infusion which also reduces their body weight, adiposity, and food intake.
In contrast, LepR antagonist administration surprisingly increases feeding and body weight in
both lean and DIO mice [47]. Obesity also reduces the anorexigenic effects of leptin [31]. The
intraperitoneal administration of leptin induces an equivalent number of cells expressing
pSTAT3 in the VMH, DMH, and NTS of high fat diet-induced obese mice, compared to lean
animals on normal chow diet. The anatomical position of LepR-expressing cells in relation to
the BBB is the probable cause of selective leptin resistance [48], and this type of resistance may
be also present in peripheral tissues [49].
Leptin enters into the CNS through a saturated transport system. The cerebrospinal fluid to
serum leptin ratio is decreased in obesity. Central leptin infusions are more efficient than pe-
ripheral injections in inducing the anorexigenic effects of leptin in obese animals. This suggests
that leptin is transported from systemic circulation to the CNS by the short forms of LepR,
namely obRa, and mutant rats with a deficiency of synthesizing obRa develop obesity due to
decreased leptin transport across the BBB [31]. In addition, the obRa present in brain micro-
vessels and choroid plexus mediates the transcellular transport of leptin. Circulating leptin
activates ERK signaling pathway in median eminence tanycytes and allows leptin passage to the
cerebrospinal fluid [50]. The activation of the LepR/JAK2/STAT3 signaling pathway induces a
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robust expression of STAT transcription factors, which in turn regulate the transcription of
genes from the SOCS family, including 8 intracellular proteins named SOCS1 to SOCS7, and
CIS. The major protein SOCS3 inhibits leptin signaling, and the increased SOCS3 levels in
LepR-expressing cells is the principal cause of leptin resistance in obesity [31].
In addition, protein tyrosine phosphatases (PTPs) catalyze the dephosphorylation of tyrosine
residues and inhibit leptin signaling through the dephosphorylation of LepR, JAK2 or STAT3 [51].
The hypothalamic expression of PTPs is increased in obese animals, and selective ablation of these
proteins improves leptin sensitivity and partially prevents high fat DIO and insulin resistance [52].
Leptin resistance is caused by mutations in the genes encoding leptin and its receptors as well
as proteins involved in the self-regulation of leptin synthesis and the permeability of BBB [53].
Thus a number of potential mechanisms, which impair LepR signaling in obesity and permit
positive energy balance, are the obesity-induced inhibitors of the LepR signaling pathway, the
activation of inflammatory signaling pathways and cytokines or ER stress in the hypothalamus
or hypothalamic gliosis [46].
LEPTIN AS A DRUG TARGET FOR OBESITY
Leptin has a potential role as a therapeutic target. The discovery of any treatment capable of
preventing or curing the condition of leptin resistance will have a tremendous potential as anti-
obesity therapy [54]. Fc-leptin is used for the treatment of non-leptin-deficient obese humans
[35]. In healthy humans leptin causes ongoing weight loss after 12 weeks of dietary fat restriction
[55]. The intracellular protein SOCS3 is a potential target for therapeutic intervention, because it
acts as a leptin-induced negative regulator of leptin receptor signaling and an effective mediator
of leptin resistance [56]. In addition, in human obesity PTP1B (a leptin-resistance-inducing
protein) has also been suggested to be a potential target for the treatment of leptin resistance [35].
Many natural products containing several lignans and flavonoids can inhibit PTP1B [57].
Resveratrol activates SIRT1, a NADþ-dependent protein deacetylase, which modulates leptin and
insulin sensitivity [58]. Celastrol, a pentacyclic triterpene, or withaferin A, a steroidal lactone, are
leptin sensitizer compounds and have powerful anti-obesity properties [59, 60]. In addition,
concurrent peripheral administration of leptin and amylin (a hormone co-secreted with insulin
from pancreatic b-cells that binds to specific receptors in the hindbrain) causes synergistic
anorexigenic effects in DIO animals. This indicates that amylin agonists restore leptin respon-
siveness in DIO. Exendin-4 (a long-acting GLP-1 receptor agonist) or fibroblast growth factor
also induces leptin responsiveness in DIO mice. Moreover, treatment of obese mice by leptin-
neutralizing antibodies for 6 weeks has been found to result in a 10% reduction of food intake
[61]. Recent clinical data also suggest that obesity, disturbed glucose homeostasis and sleep apnea
are interrelated phenomena, and treating one of them can improve the others [62].
MODULATION OF DIET TO STIMULATE THE SECRETION OR ENHANCE THE
ACTION OF LEPTIN
Diet plays an important role in controlling obesity. Regarding meal composition, which is a
determinant of leptin level in obese humans, low-fat/high-carbohydrate meals result in an
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increase in circulating leptin concentrations compared with high-fat/low-carbohydrate meals
[35]. It has been found that intake of carbohydrates with high glycemic index increases leptin
concentration [63]. The presence of high amount of fibers in the diet enhances leptin sensitivity
as well as controls the secretion of leptin [64]. Diets enriched with u3 and u6 polyunsaturated
fatty acids (PUFA) cause the increase in the circulating level of leptin compared to a diet
enriched in monounsaturated fatty acids (MUFA) and saturated fatty acids (SFA) [65]. When
protein consumption is higher, it increases satiety, leptin concentration as well as leptin
sensitivity in the central nervous system to control body weight [66] (Fig. 1).
LEPTIN AND PHYSICAL EXERCISE
In obese women a 9-week aerobic exercise program did not change resting serum leptin levels,
suggesting that women with a higher degree of obesity have a higher degree of leptin resistance
and a larger volume of exercise is needed to affect the levels of leptin [67]. Perusse et al. 1997
[68] showed that in men a 20-week aerobic exercise program significantly decreased leptin
concentrations. Different studies suggest that long-term exercise (≥60 min) and exercises that
cause energy expenditure equal to or higher than 800 kcal decrease the circulating leptin con-
centration [69], whereas short-term exercises (<60 min) and exercises that cause energy
expenditure lower than 800 kcal fail to modify the levels of circulating leptin [70]. Regarding the
effects of exercise training on circulating leptin, it has been found that in healthy young and
older males short-term aerobic training for 7 successive days does not modify leptin concen-
trations [71], whereas a reduction in leptinemia has been found after 3 weeks of military
training, but the body weight remains stable [72]. Thus circulating leptin shows different
Fig. 1. An idealized model depicting the mode of leptin actions in developing obesity. HT, Hypothalamus;
POMC, Pro-opiomelanocortin; AgRP, Agouti-related peptide; GABA, g-Aminobutyric acid; GLP1,
Glucagon-like peptide 1; NTS, Nucleus tractus solitarius; BAT, Brown adipose tissue; NPY, Neuropeptide
Y; CART, Cocaine and amphetamine-related transcript
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responses to short-term (<12 weeks) and long-term training (≥12 weeks) [69], and during
exercise leptin regulates the energy balance by increasing energy expenditure as well as reducing
total body fat [73]. It has been suggested that the decrease in the level of insulin, the known
stimulant of the expression of leptin in adipose tissue, takes place prior to the reduction of leptin
and thus it may be considered as a mediator of leptin concentrations [74]. Although exercise
improves leptin sensitivity in peripheral tissues or in the hypothalamus in obese animals, acute
exercise suppresses hypothalamic PTP1B protein levels, resulting in more activation of insulin
and leptin signaling pathways in obese rats [31].
ADIPOSE TISSUE IMMUNITY, LEPTIN, AND CANCER
In case of excess energy consumption with little or no physical exercise, obese individuals
may sometimes develop proinflammatory condition in their adipose tissue cells due to
infiltration of monocytes, macrophages, neutrophils and mast cells from the innate and B and
T lymphocytes from the acquired immune system [75]. Furthermore, the intracellular
accumulation of interferon-g, monocyte chemotactic protein-1, tumor necrosis factor a,
interleukin-6 and -1b transform the proinflammatory condition into a state of inflammation
[76]. All these changes create a microenvironment in the adipocytes upon which leptin can
act as the mitogenic, antiapoptotic, and angiogenic signaling molecule to promote carcino-
genesis [77].
Leptin has been found to be associated with breast, ovarian, endometrial, prostate, colorectal,
lung, pancreatic, adrenal, pituitary, and thyroid cancers [75–78]. After menopause in women,
the adipose tissues serve as the main source of estrogen. Postmenopausal obese women are more
prone to develop breast cancer than premenopausal lean women, indicating the existence of
positive correlations between blood titers of leptin and estrogen, and also the tissue-specific
expression of their receptors [79, 80]. In addition, leptin can regulate the expression of several
proteins viz. p53, cyclin D1, E-cadherin, survivin, vascular endothelial growth factor and its
receptor subtype 2 involved in carcinogenesis, and also stimulate the production of interleukin-8
and -18 by macrophages for cancer metastasis [80].
FUTURE PERSPECTIVES
It is obvious from the discussion that calorie intake, diet therapy and physical exercise maintain
a complex relationship among themselves. Keeping this in consideration, the following studies
may be envisaged to restrict the problems of obesity within a physiological limit.
(a) Due to blunted response of leptin to calorie intake the leptin resistance state develops. The
ability of leptin replacement to reverse the obesity-related changes suggests that leptin itself
or drugs stimulating the leptin signaling pathway may provide opportunities for the
maintenance of weight loss.
(b) On the other hand, how supplementation of weight-reducing substances in diet along with
or without training programs of physical exercise can influence the action of leptin in target
cells may be another subject for future study.
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